James Hamilton
Corporate Officer/Principal at ARROWHEAD PHARMACEUTICALS, INC.
Net worth: 6 M $ as of 2024-03-30
Profile
James C.
Hamilton is the founder of NanoValent Pharmaceuticals, Inc. (founded in 2005).
He is currently the Chief Discovery & Translational Medicine at Arrowhead Pharmaceuticals, Inc. He was formerly the Chief Executive Officer at Calando Pharmaceuticals, Inc. Dr. Hamilton received his undergraduate degree from Miami University and his MBA and doctorate degrees from The Ohio State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-31 | 204,851 ( 0.17% ) | 6 M $ | 2024-03-30 |
James Hamilton active positions
| Companies | Position | Start |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| NanoValent Pharmaceuticals, Inc. | Founder | 2010-02-22 |
Former positions of James Hamilton
| Companies | Position | End |
|---|---|---|
Calando Pharmaceuticals, Inc.
 Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calando Pharmaceuticals, Inc. engages in the design and development of drug-delivery-enhanced small molecule therapeutics. The company was established in 2000 and is headquartered in Pasadena, CA. | President | - |
Training of James Hamilton
| Miami University | Undergraduate Degree |
| The Ohio State University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Calando Pharmaceuticals, Inc.
Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calando Pharmaceuticals, Inc. engages in the design and development of drug-delivery-enhanced small molecule therapeutics. The company was established in 2000 and is headquartered in Pasadena, CA. | Health Technology |
| NanoValent Pharmaceuticals, Inc. |
- Stock Market
- Insiders
- James Hamilton
